SVRA Savara, Inc.
$4.86▲ +7.52%
Healthcare
Other
After hours
$4.75▼ -2.29%
Oct 27, 5:34 PM ET
Volume 3.59M
Avg Volume (10D) 2.73M
Key Metrics & Fundamentals
Market Cap
$998.54M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.86 - 7.01
% vs 50 MA
-4.85%
% vs 200 MA
-10.10%
RSI-14
50.8
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.34
Free Cash Flow
-$29.97M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$40.77M
COGS
–
Operating Exp
$40.97M
Operating Income
-$40.97M
EBIT
-$40.97M
Pretax Income
-$40.23M
Net Income
-$40.23M
EPS (Diluted)
-0.16
Price & Volume History
Loading chart…
Recent News
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Business Wire · Oct 21, 2026 1:10 PM ET
Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?
Simply Wall St. · Oct 13, 2026 4:14 AM ET
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Business Wire · Oct 12, 2026 4:05 PM ET
Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside
TIKR · Oct 11, 2026 12:43 PM ET
JPMorgan Initiates Savara at Overweight With $12 Price Target
MT Newswires · Oct 7, 2026 8:18 AM ET
Top Premarket Gainers
MT Newswires · Oct 6, 2026 7:12 AM ET
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Business Wire · Aug 24, 2026 4:05 PM ET
Savara Announces New Employment Inducement Grant
Business Wire · Aug 20, 2026 4:05 PM ET
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · Aug 11, 2026 4:05 PM ET
What Insmed Stock's Premium Is Actually Buying
Trefis · Aug 7, 2026 11:39 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SVRA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.